The purpose of the article is to investigate the effects of topical azithromycin 1% (Azasite) in treating acute ocular inflammation related to long standing pterygium. A prospective interventional study of 8 consecutive cases with pterygium presenting to our University Eye Clinics over the period of one month with acute symptoms of red eye(s) and irritation. After patient education and receipt of consent to the study, patients were treated with topical azithromycin 1% (Azasite) twice a day for the first two days and once a day for the next 12 days. Anterior segment photo was taken before treatment and 3-day and/or 7-day after treatment in addition to eye examination. Six out of the eight cases reported of significant improvement or resolution of signs and symptoms on the follow up visits. One severe case did not respond as well after a week of treatment and was successfully managed by topical prednisolone. Another case did not comply with the study protocol. In this small pilot study, Azasite was effective in management of acute mild to moderate ocular inflammation triggered by ocular surface disease, including pterygium. Severe ocular inflammation may require more potent anti-inflammatory therapy like topical steroids.

The purpose of the article is to investigate the effects of topical azithromycin 1% (Azasite) in treating acute ocular inflammation related to long standing pterygium. A prospective interventional study of 8 consecutive cases with pterygium presenting to our University Eye Clinics over the period of one month with acute symptoms of red eye(s) and irritation. After patient education and receipt of consent to the study, patients were treated with topical azithromycin 1% (Azasite) twice a day for the first two days and once a day for the next 12 days. Anterior segment photo was taken before treatment and 3-day and/or 7-day after treatment in addition to eye examination.